article thumbnail

Promising schizophrenia drug faces tough competition

European Pharmaceutical Review

According to the pre-IND meeting with the US Food and Drug Administration (FDA), Luye Pharma plans to submit the New Drug Application (NDA) for LY03010 to the FDA through the 505(b)(2) pathway. The post Promising schizophrenia drug faces tough competition appeared first on European Pharmaceutical Review.

article thumbnail

Biosimilar competition saves US healthcare $21 billion

European Pharmaceutical Review

Amgen’s 2022 market report has detailed how competition has driven savings across healthcare, estimating that a considerable number of biologics will be in competition with biosimilars in five to 10 years. A rise in savings per quarter was recognised in this year’s data. Seven more are expected to be launched in 2023.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Anesthesia Sales, Surgery, And Strategy With Marie Robert

Evolve Your Success

The podcast takes a fascinating turn when we explore Marie’s insights into the supportive, non-competitive environment at GE’s commercial leadership program, especially during the tumultuous COVID pandemic. Marie also shares her strategies for achieving work-life balance amidst the competitive landscape of medical sales.

Sales 130
article thumbnail

Can we get healthcare right?

World of DTC Marketing

Innovation and Competition Act. Information on public assistance and food stamps. And to stop Americans from getting cheaper prescriptions, he is willing to sabotage American manufacturers (and therefore assist China) by denying them $52 billion in support under the U.S. Government assistance programs include: U.S. 800-677-1116.

article thumbnail

ESMO 2022: shrinking market for Trodelvy, with fierce ADC competition

Pharmaceutical Technology

While Trodelvy is expected to be the first ADC approved in the HR+/HER2-negative breast cancer setting, Daiichi / AstraZeneca’s Enhertu (trastuzumab deruxtecan) received US Food and Drug Administration (FDA) approval just last month for patients with HER2-low expressing breast cancers.

article thumbnail

Is Your Sales Training Doing Any Good?

Integrity Solutions

How comfortable are you taking your current salespeople—with the level of performance and skills they have right now—into an increasingly competitive marketplace? I probably can’t win in such a competitive market. The business environment isn’t getting any easier to navigate. I’m afraid I can’t make that quota. (a

article thumbnail

Tariffs could threaten medicine innovation, industry bodies warn

European Pharmaceutical Review

According to the findings, nearly 90 percent of US biotechs rely on imported components for at least half of their products approved by the US Food and Drug Administration. This makes supply of medicines vulnerable especially to proposed tariffs on the EU, China, and Canada, according to BIO.